≡Menu

Category Archives: Antitrust

July 07

Antitrust

FTC Antitrust Enforcement Blocks Anticompetitive Coordination in Global Advertising Merger

On June 25, 2025, the Federal Trade Commission (FTC) approved a merger between two of the largest advertising agencies, Omnicom and Interpublic, contingent upon their compliance with a proposed order. This antitrust enforcement order will “prevent Omnicom from engaging in collusion or coordination to direct advertising away from media publishers based on the publishers’ political or ideological viewpoints” (article). Omnicom and Interpublic are two out of six major global advertising…

May 27

Antitrust

Athletes Await Final Approval of $2.8 Billion NCAA Antitrust Settlement

In one of the most consequential moments in college sports history, a federal judge in the Northern District of California, has declined final approval to a $2.8 billion antitrust settlement between the NCAA, its major conferences, and thousands of current and former Division I athletes. In October of 2024, Judge Wilken, preliminarily approved the settlement – a deal that would have ended a years-long legal battle over athlete compensation and…

April 23

Antitrust

Judge Approves $375 Million UFC Antitrust Settlement

In a historic moment for sports law and antitrust litigation, a federal judge has granted final approval to a $375 million UFC antitrust settlement. The deal resolves a decade-long class action lawsuit filed by a group of professional mixed martial arts fighters, who accused the UFC of fighter wage suppression through monopolistic market control. Reaching this settlement was a life-changing victory for the fighters and a watershed moment for future…

April 05

Antitrust

Miller Shah Secures Partial Summary Judgment in ACTOS Antitrust Litigation While the Trial is Delayed as the Case Awaits a Decision from the Second Circuit on the Class Certification Order

The case was originally filed in 2013 and has already taken two trips to the Second Circuit Court of Appeals. The certified class of End-Payors accuse Takeda of violating the law by “misdescribing” its patent rights to the FDA. Plaintiffs allege that Takeda unlawfully engaged in anticompetitive and monopolistic conduct which inflated the price of its diabetes treatment, Actos (pioglitazone), by delaying the entry of generic alternatives and causing inflated…

April 14

Class Action, Antitrust

J&J Anti-Inflammatory Medication Swells Consumer Prices

On March 15, 2023, the Honorable Karen Marston of the United States District Court for the Eastern District of Pennsylvania granted final approval of a $39.8 million settlement (“Settlement”) to resolve antitrust claims against Johnson & Johnson (“J&J” or the “Company”) alleging that the company launched its “Biosimilar Readiness Plan” to block health care providers from purchasing competitor products of its infliximab biosimilar, Remicade. The Settlement previously received preliminary approval…

March 17

Antitrust

Judge Grants Final Approval to $33 Million Settlement in Salmon Anti-Trust Suit

On February 27, 2023, the Honorable Rodney Smith of the United States District Court for the Southern District of Florida granted final approval of a $33 million settlement (“Settlement”) to resolve anti-trust claims brought against Norwegian salmon farming companies Mowi ASA, Grieg Seafood ASA, Ocean Quality AS, Salmar ASA, Cermaq, and Lerøy Seafood USA Inc. (collectively, “Defendants”). The settlement received Preliminary Approval on October 6, 2022. This action was originally…

February 07

Employment, Antitrust

FTC Proposes Ban on Employment-Related Non-Compete Clauses

On January 5, 2023, the Federal Trade Commission (“FTC”) unveiled a Notice of Proposed Rulemaking (“NPRM”) that would ban virtually all employment-related non-compete agreements (“NCAs”) on the ground that such agreements are an “unfair method of competition,” thereby violating Section 5 of the FTC Act. Non-compete agreements are clauses in employment contracts that prohibit employees from working for competing companies for a defined period following the employee’s departure from the contracting…

November 08

Antitrust

AstraZeneca, Handa, and Par Pharmaceuticals to Face Seroquel XR Antitrust Lawsuit

On July 5, 2022, the Honorable Colm F. Connolly of the United States District Court for the District of Delaware denied the motion to dismiss an antitrust lawsuit against AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. (“AstraZeneca”); Handa Pharmaceuticals, LLC (“Handa”); and Par Pharmaceutical, Inc. (“Par”) (collectively, “Defendants”). The lawsuit alleges that Defendants engaged in monopolistic behavior to delay the production of a generic form of AstraZeneca’s antidepressant drug Seroquel XR…

November 04

Antitrust, Class Action

Norwegian Salmon Antitrust Case Nets $33 Million Settlement

On October 6, 2022, a proposed class of indirect salmon buyers (the “Settlement Class”) obtained a class-wide settlement of $33 million to resolve antitrust claims against Norwegian salmon producers, alleging that they inflated farm-raised salmon prices in the United States. In the preliminary approval motion, counsel for the Settlement Class indicated that the settlement is “an excellent result for the class” since it would avoid lengthy litigation and the uncertainties…

While this website provides general information, it does not constitute legal advice. The best way to get guidance on your specific legal issue is to contact a lawyer. To schedule a meeting with an attorney, please call 866-540-5505 or complete the intake form to email us. To inquire about employment opportunities with Miller Shah LLP, please see our Opportunities page.

Offices Throughout
the United States & Italy

Get Fort Lauderdale Directions

IT Milan

Fax number

866-540-5505

Telephone

Attorney Advertising. This information is designed for general information only. The information presented should not be construed to be formal legal advice nor the formation of a lawyer/client relationship. Past results and testimonials are not a guarantee, warranty, or prediction of the outcome of your case, and should not be construed as such. Past results cannot guarantee future performance. Any result in a single case is not meant to create an expectation of similar results in future matters because each case involves many different factors, therefore, results will differ on a case-by-case basis. By providing contact information, users acknowledge and give explicit consent to be contacted via the methods of communication provided, including SMS. Message and data rates may apply. Message frequency may vary. Reply STOP to opt out.